Skip to main content

On-Demand Therapy with Rabeprazole in Nonerosive and Erosive Gastroesophageal Reflux Disease in Clinical Practice: Effectiveness, Health-Related Quality of Life, and Patient Satisfaction

Digestive Diseases and Sciences volume 49, pages 931–936 (2004)Cite this article

Abstract

On-demand therapy is effective for maintaining symptoms control in nonerosive gastroesophagealreflux disease (GERD). Our aim was to assess the clinical effectiveness of on-demand therapy witha proton pump inhibitor (PPI) in mild GERD (nonerosive and low-grade esophagitis), its impact onhealth-related quality of life (HRQoL), and the degree of patient satisfaction. Fifty-five patients (17with nonerosive GERDand 38 with low-grade esophagitis) were treated with rabeprazole, 20 mg/day.The healed patients started on-demand therapy. We evaluated symptoms (clinical questionnaire),HRQoL (SF-36 questionnaire), and patient satisfaction (visual analogue scale). Of the 55 patientsincluded, 51 started on-demand therapy for 6 months. Symptom control (heartburn <twice a week)was achieved in over 85% of the patients. The mean (SD) amount of PPI used was 0.3 (0.19)tablet/day. The patient satisfaction score at the end of the acute phase was 98 (range, 0-100) andremained high (90; range, 10-100) and stable during on-demand therapy. Short-term treatmentnormalized the HRQoL scores, which were subsequently maintained during on-demand therapy.On-demand therapy is useful for the clinical management of patients with mild GERD, allowingadequate symptoms control, limiting PPI consumption, and affording important patient satisfactionwith normalization of HRQoL.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

REFERENCES

  1. Heading RC. Prevalence of upper gastrointestinal symptoms in the general population: A systematic review. Scand J Gastroenterol 231(Suppl): 3–8, 1999

    Google Scholar 

  2. Johanson JF: Epidemiology of esophageal and supraesophageal reflux injuries. Am J Med 108(Suppl 4A): 99S–103S, 2000

    Google Scholar 

  3. Revicki DA, Wood M, Maton PN, Sorensen S: The impact of gastroesophageal reflux disease on health-related quality of life. Am J Med 104: 252–258, 1998

    Google Scholar 

  4. Havelund T, Lind T, Wiklund I, Glise H, Hernqvist H, Lauritsen K, Lundell L, Pedersen SA, Carlsson R, Junghard O, Stubberod A, Anker-Hansen O: Quality of life in patients with heartburn but without esophagitis: Effects of treatment with omeprazole. Am J Gastroenterol 94: 1782–1789, 1999

    Google Scholar 

  5. Gralnek IM, Hays RD, Kilbourne A, Naliboff B, Mayer EA: The impact of irritable bowel syndrome on health-related quality of life. Gastroenterology 119: 654–660, 2000

    Google Scholar 

  6. Eloubeidi MA, Provenzale D: Health-related quality of life and severity of symptoms in patients with Barrett's esophagus and gastroesophageal reflux disease patients without Barrett's esophagus. Am J Gastroenterol 95: 1881–1887, 2000

    Google Scholar 

  7. Chiba N, De Gara CJ, Wilkinson JM, Hunt RH: Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: A meta-analysis. Gastroenterology 112: 1798–1810, 1997

    Google Scholar 

  8. van Pinxteren B, Numans ME, Bonis PA, Lau J: Short-term treatment with proton pump inihibitors, H2-receptor antagonists and prokinetics for gastroesophageal reflux disease-like symptoms and endoscopy negative reflux disease (Cochrane Review). The Cochrane Library, Issue 2, Oxford, Update Software, 2000

    Google Scholar 

  9. Schindlbeck NE, Klauser AG, Berghammer G, Londong W, Muller-Lissner SA: Three year follow-up of patients with gastroesophageal reflux disease. Gut 33: 1016–1019, 1992

    Google Scholar 

  10. Carlsson R, Dent J, Watts R, Riley S, Sheikh R, Hatlebakk J, Haug K, de Groot G, van Oudvorst A, Dalvag A, Junghard O, Wiklund I. Gastroesophageal reflux disease in primary care: An international study of different treatment strategies with omeprazole. International GORDStudy Group. Eur J Gastroenterol Hepatol 10: 119–124, 1998

    Google Scholar 

  11. Dent J, Brun J, Fendrick AM, Fennerty MB, Janssens J, Kahrilas PJ, Lauritsen K, Reynolds JC, Shaw M, Talley NJ: An evidence-based appraisal of reflux disease management—The Genval Workshop report. Gut 44(Suppl 2): S1–S16, 1999

    Google Scholar 

  12. Bardhan KD, Muller-Lissner S, Bigard MA, Porro GB, Ponce J, Hosie J, Scott M, Weir DG, Gillon KR, Peacock RA, Fulton C: Symptomatic gastroesophageal reflux disease: Double blind controlled study of intermittent treatment with omprazole or ranitidine. Br Med J 318: 502–507, 1999

    Google Scholar 

  13. Lind T, Havelund T, Lundell L, Glise H, Lauritsen K, Pedersen SA, Anker-Hansen O, Stubberod A, Eriksson G, Carlsson R, Junghard O: On-demand therapy with omeprazole for the long-term management of patients with heartburn without oesophagitis—A placebo-controlled randomized trial. Aliment Pharmacol Ther 13: 907–914, 1999

    Google Scholar 

  14. Talley NJ, Lauritsen K, Tunturi-Hihnala H, Lind T, Moum B, Bang C, Schulz T,Omland TM, Delle M, Junghard O: Esomeprazole 20 mg maintains symptom control in endoscopy-negative gastroesophageal reflux disease: a controlled trial of “on-demand” therapy for 6 months. Aliment Pharmacol Ther 15: 347–354, 2001

    Google Scholar 

  15. Talley NJ, Venables TL, Green JR, Armstrong D, O'Kane KP, Giaffer M, Bardhan KD, Carlsson RG, Chen S, Hasselgren GS: Esomeprazole 40 mg and 20 mg is efficacious in the long-term management of patients with endoscopy-negative gastroesophageal reflux disease: A placebo-controlled trial of on-demand therapy for 6 months. Eur J Gastroenterol Hepatol 14: 857–863, 2002

    Google Scholar 

  16. Armstrong D, Bennett JR, Blum AL, Dent J, De Dombal FT, Galmiche JP, Lundell L, Margulies M, Richter JE, Spechler SJ, Tytgat GN, Wallin L: The endocopic assessment of esophagitis: A progress report on observer agreement. Gastroenterology 111: 85–92, 1996

    Google Scholar 

  17. Ware JE, Sherbourne CD: The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 30: 473–483, 1992

    Google Scholar 

  18. Alonso J, Prieto L, Anto JM: The spanish version of the SF-36 health survey (the SF-36 health questionnaire): An instrument for measuring clinical results. Med Clin (Barc) 104: 771–776, 1995

    Google Scholar 

  19. Alonso J, Regidor E, Barrio G, Prieto L, Rodriguez C, De la Fuente L: Population reference values of the Spanish version of the Health Questionnaire SF-36. Med Clin (Barc) 111: 410–416, 1998

    Google Scholar 

  20. Compte L, Garrigues V, Perpiñá M, Ponce J: Prevalence of gastroesophageal reflux in asthma. J Asthma 37: 175–182, 2000

    Google Scholar 

  21. Gerson LB, Robbins AS, Garber A, Hornberger J, Triadafilopoulos G: A cost-effectiveness analysis of prescribing strategies in the management of gastroesophageal reflux disease. AmJ Gastroenterol 95: 395–407, 2000

    Google Scholar 

  22. Dekkers CP, Beker JA, Thjodleifsson B, Gabryelewicz A, Bell NE, Humphries TJ: Double-blind comparison of rabeprazole 20 mg vs. omeprazole 20 mg in the treatment of erosive or ulcerative gastroesophageal reflux disease. The European Rabeprazole Study Group. Aliment Pharmacol Ther 13: 49–57, 1999

    Google Scholar 

  23. Miner P, Orr W, Filippone J, Jokubaitis L, Sloan S: Rabeprazole in nonerosive gastroesophageal reflux disease: A randomized placebo-controlled trial. Am J Gastroenterol 97: 1332–1339, 2002

    Google Scholar 

  24. Robinson M, Fitzgerald S, Hegedus R, Murthy A, Jokubaitis L: Onset of symptom relief with rabeprazole: A community-based, open-label assessment of patients with erosive oesophagitis. Aliment Pharmacol Ther 16: 445–454, 2002

    Google Scholar 

  25. Dent J, Talley NJ: Overview: Initial and long-term management of gastroesophageal reflux disease. Aliment Pharmacol Ther 17(Suppl 1): 53–57, 2003

    Google Scholar 

  26. Bytzer P: On-demand therapy for gastroesophageal reflux disease. Eur J Gastroenterol Hepatol 13(Suppl 1): S19–S22, 2001

    Google Scholar 

  27. Williams MP, Sercombe J, Hamilton MI, Pounder RE: A placebo-controlled trial to assess the effects of 8 days of dosing with rabepra-zole versus omeprazole on 24-hour intragastric acidity and plasma gastrin concentrations in young healthy male subjects. Aliment Pharmacol Ther 12: 1079–1089, 1998

    Google Scholar 

  28. Heading RC: Long-term management of gastro oesophageal reflux disease. Scand J Gastroenterol 30(Suppl 213): 25–30, 1995

    Google Scholar 

  29. Hungin AP, Rubin G, O'Flanagan H: Factors influencing compliance in long-term proton pump inhibitor therapy in general practice. Br J Gen Pract 49: 463–464, 1999

    Google Scholar 

  30. Johanson JF, Siddique R, Damiano AM, Jokubaitis L, Murthy A, Bhattacharjya A: Rabeprazole improves health-related quality of life in patients with erosive gastroesophageal reflux disease. Dig Dis Sci 47: 2574–2578, 2002

    Google Scholar 

  31. Stalhammar NO, Carlsson J, Peacock R, Muller-Lissner S, Bigard MA, Porro GB, Ponce J, Hosie J, Scott M, Weir DG, Fulton C, Gillon K, Bardhan KD: Cost effectiveness of omeprazole and ranitidine in intermittent treatment of symptomatic gastroesophageal reflux disease. Pharmacoeconomics 16: 483–497, 1999

    Google Scholar 

  32. Wahlqvist P, Junghard O, Higgins A, Green J: Cost-effectiveness of proton pump inhibitors in gastroesophageal reflux disease without oesophagitis: comparison of on-demand esomeprazole with conventional omeprazole strategies. Pharmacoeconomics 20: 267–277, 2002

    Google Scholar 

  33. Inadomi JM: On-demand and intermittent therapy for gastroesophageal reflux disease: Economic considerations. Pharmacoeconomics 20: 565–576, 2002

    Google Scholar 

Download references

Authors
  1. Julian Ponce
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lidia Argüello
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Guillermo Bastida
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Marta Ponce
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Vicente Ortiz
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Vicente Garrigues
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Ponce, J., Argüello, L., Bastida, G. et al. On-Demand Therapy with Rabeprazole in Nonerosive and Erosive Gastroesophageal Reflux Disease in Clinical Practice: Effectiveness, Health-Related Quality of Life, and Patient Satisfaction. Dig Dis Sci 49, 931–936 (2004). https://doi.org/10.1023/B:DDAS.0000034551.39324.c3

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/B:DDAS.0000034551.39324.c3

  • gastroesophageal reflux disease
  • proton pump inhibitors
  • on-demand therapy
  • quality of life